作者
Manuel E Baldeón, Augusto Maldonado, Miguel Ochoa‐Andrade, Carolina Largo, Mónica Pesantez, Marco Herdoiza, Gerardo Granja, Marco Bonifaz, Hugo Espejo, Francisco Mora, Patricio Abril‐López, Lady Karen Robles Armijo, Verónica Pacheco, Rafael Salazar, Steffy Reinthaller, Federico Zertuche, Marco Fornasini
发表日期
2022/4
期刊
Transfusion Medicine
卷号
32
期号
2
页码范围
153-161
出版商
Blackwell Publishing Ltd
简介
Introduction
South America is one of the regions most affected by the COVID‐19 pandemic. Specific and affordable treatments are needed to treat SARS‐CoV‐2 infection. Evidence regarding the use of convalescent plasma in COVID‐19 patients is still limited. We compared the safety and efficacy of COVID‐19‐convalescent plasma administration as a complement to standard treatment in the early management of patients with moderate SARS‐CoV‐2 infection.
Methods
We carried out a random double blinded, placebo‐controlled trial that compared standard treatment plus convalescent plasma (CP) or plus non‐convalescent plasma in the management of COVID‐19 patients. The main outcome was survival and secondary endpoints included: length of hospitalisation (LOH), days from treatment to discharge, time to clinical improvement or death within a 28‐day period, and adverse reactions to treatment.
Results …
学术搜索中的文章
ME Baldeón, A Maldonado, M Ochoa‐Andrade… - Transfusion Medicine, 2022